Here's a sobering reality check: 48.4 million Americans aged 12 and older are battling substance use disorders right now. Yet only 20% of those affected ever receive any form of pharmacological treatment. Even more striking, 95.6% of adults with these conditions don't believe they need help at all.
This massive disconnect between need and treatment is driving one of healthcare's most complex market dynamics. The global substance use disorder treatment market, valued at $11.6 billion in 2025, is projected to reach $14.6 billion by 2030, growing at 4.6% annually. North America leads with 36.6% of the market, but the growth drivers tell a story that spans far beyond geography.
The opioid crisis has pushed governments to pour funding into response programs, while healthcare providers are finally getting better at screening and prescribing appropriate treatments. Innovation is accelerating too, with companies like Indivior, Alkermes, and Camurus developing long-acting injectable formulations that solve the compliance problem. Even more intriguing, psychedelics are emerging as a legitimate therapeutic class for addiction treatment.
But the real opportunity lies in addressing that treatment gap. When 70% of smokers globally lack access to cessation services, and stigma still prevents people from seeking help, there's enormous room for market expansion. New abuse-deterrent formulations, intranasal rescue medications, and even genetically targeted therapies are starting to chip away at these barriers.
Want the full picture? Download the free overview of our report Substance Use Disorder Treatment: Global Markets to 2030 for detailed market forecasts, competitive landscapes, and emerging treatment innovations.
